Allen Richard C, Engelstädter Jan, Bonhoeffer Sebastian, McDonald Bruce A, Hall Alex R
Institute of Integrative Biology, ETH Zürich, CH-8092 Zurich, Switzerland
School of Biological Sciences, The University of Queensland, Brisbane, Queensland 4072, Australia.
Proc Biol Sci. 2017 Sep 27;284(1863). doi: 10.1098/rspb.2017.1619.
Resistance spreads rapidly in pathogen or pest populations exposed to biocides, such as fungicides and antibiotics, and in many cases new biocides are in short supply. How can resistance be reversed in order to prolong the effectiveness of available treatments? Some key parameters affecting reversion of resistance are well known, such as the fitness cost of resistance. However, the population biological processes that actually cause resistance to persist or decline remain poorly characterized, and consequently our ability to manage reversion of resistance is limited. Where do susceptible genotypes that replace resistant lineages come from? What is the epidemiological scale of reversion? What information do we need to predict the mechanisms or likelihood of reversion? Here, we define some of the population biological processes that can drive reversion, using examples from a wide range of taxa and biocides. These processes differ primarily in the origin of revertant genotypes, but also in their sensitivity to factors such as coselection and compensatory evolution that can alter the rate of reversion, and the likelihood that resistance will re-emerge upon re-exposure to biocides. We therefore argue that discriminating among different types of reversion allows for better prediction of where resistance is most likely to persist.
在接触杀生物剂(如杀菌剂和抗生素)的病原体或害虫种群中,抗药性迅速传播,而且在许多情况下,新型杀生物剂供应短缺。如何逆转抗药性以延长现有治疗方法的有效性?一些影响抗药性逆转的关键参数是众所周知的,比如抗药性的适合度代价。然而,实际导致抗药性持续存在或下降的种群生物学过程仍鲜为人知,因此我们管理抗药性逆转的能力有限。取代抗性谱系的敏感基因型来自何处?逆转的流行病学规模是怎样的?我们需要哪些信息来预测逆转的机制或可能性?在此,我们利用来自广泛分类群和杀生物剂的实例,定义一些能够推动逆转的种群生物学过程。这些过程的主要区别在于回复突变基因型的来源,但在对共选择和补偿进化等因素的敏感性方面也存在差异,这些因素会改变逆转速率以及再次接触杀生物剂时抗药性重新出现的可能性。因此,我们认为区分不同类型的逆转有助于更好地预测抗药性最有可能持续存在的地方。